Additional Relevant Details One of the two oral presentations – updated data from the ongoing Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of GBT440, a HbS Polymerization Inhibitor – has been selected to be featured in an ASH press briefing.